Adaptive licensing: Is the EMA's Rasi heading for a fight with the commission and others in EU?
This article was originally published in SRA
Executive Summary
The European Commission and German health technology assessors have poured cold water on aspirations by European Medicines Agency head Guido Rasi to introduce an adaptive licensing approach for evaluating and approving medicines.
You may also be interested in...
EMA Defends Adaptive Pathways Against Fresh Attack Following Pilot Report
The European Medicines Agency has dismissed a call to stop accepting applications for its adaptive pathways program until it has better evidence on how to use real-world data.
Adaptive Pathways: Companies Advised To Consider Hurdles As EMA Accepts More Applications
The European Medicines Agency has released its keenly awaited final report on it adaptive pathways pilot and says it will continue to accept applications for the new drug development concept. Meanwhile, law firm Bristows highlights the hurdles ahead for applicants.
EMA Probe Finds No Link Between GLP-1s And Suicidal Thoughts & Actions
After reviewing the evidence from non-clinical studies, clinical trials, post-marketing surveillance data and other studies, the European Medicines Agency said there was no need to update the product information for 11 diabetes and weight management drugs.